ALDX vs. INVA, CALT, AUPH, LQDA, PCRX, HROW, COLL, SYRE, GYRE, and ELVN
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Innoviva (INVA), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Liquidia (LQDA), Pacira BioSciences (PCRX), Harrow (HROW), Collegium Pharmaceutical (COLL), Spyre Therapeutics (SYRE), Gyre Therapeutics (GYRE), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical preparations" industry.
Aldeyra Therapeutics vs.
Aldeyra Therapeutics (NASDAQ:ALDX) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends.
59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 8.5% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 1.7% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Innoviva has higher revenue and earnings than Aldeyra Therapeutics.
Aldeyra Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 90.84%. Given Aldeyra Therapeutics' higher possible upside, research analysts clearly believe Aldeyra Therapeutics is more favorable than Innoviva.
Aldeyra Therapeutics received 182 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 69.35% of users gave Aldeyra Therapeutics an outperform vote while only 57.58% of users gave Innoviva an outperform vote.
Innoviva has a net margin of 18.31% compared to Aldeyra Therapeutics' net margin of 0.00%. Innoviva's return on equity of 20.84% beat Aldeyra Therapeutics' return on equity.
Aldeyra Therapeutics has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Innoviva. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 2 mentions for Innoviva. Innoviva's average media sentiment score of 1.00 beat Aldeyra Therapeutics' score of 0.29 indicating that Innoviva is being referred to more favorably in the news media.
Summary
Aldeyra Therapeutics and Innoviva tied by winning 7 of the 14 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALDX) was last updated on 2/1/2025 by MarketBeat.com Staff
